Coeptis Therapeutics Warrants
COEPW
COEPW was delisted on the 24th of April, 2026.
21 hedge funds and large institutions have $2.82M invested in Coeptis Therapeutics Warrants in 2021 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 2 closing their positions.
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
59% more capital invested
Capital invested by funds: $1.77M → $2.82M (+$1.04M)
24% more funds holding
Funds holding: 17 → 21 (+4)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCL
Glazer Capital LLC
New York
|
+$454K |
| 2 |
KC
Kepos Capital
New York
|
+$127K |
| 3 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$46.3K |
| 4 |
BFM
Boothbay Fund Management
New York
|
+$7.63K |
| 5 |
PCM
Prelude Capital Management
New York
|
+$7.63K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ES
Equitec Specialists
Chicago,
Illinois
|
-$15K |
| 2 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
-$13.9K |
| 3 |
VF
Virtu Financial
New York
|
-$5K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$102 |
COEPW Hedge Fund Activity: Q2 2021 in Review
21 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Coeptis Therapeutics Warrants (COEPW) for Q2 2021, worth a combined $2.82M — up 59% from $1.77M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new COEPW positions and 2 closed out — a net gain of 4 holders — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Glazer Capital LLC, opening a new position worth an estimated $454K. The largest seller was Equitec Specialists, exiting entirely with an estimated $15K sold.
- 21 institutional investors held Coeptis Therapeutics Warrants (COEPW) as of Q2 2021, up from 17 in Q1 2021.
- Funds reported $2.82M of Coeptis Therapeutics Warrants stock for Q2 2021, up 59% quarter-over-quarter.
- 6 funds opened new Coeptis Therapeutics Warrants positions in Q2 2021 and 2 closed out, a net change of +4 holders.
- The largest Coeptis Therapeutics Warrants buyer in Q2 2021 was Glazer Capital LLC, an estimated $454K added.
- The largest Coeptis Therapeutics Warrants seller in Q2 2021 was Equitec Specialists, an estimated $15K sold.
Based on aggregated 13F filings for Q2 2021.